Erythropoietin - Measurement and clinical applications

Annals of Clinical Biochemistry

Volumn 43, Issue 2, 2006, Pages 97-104

  Marsden, Joanne T ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 6; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT DNA; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA; VON HIPPEL LINDAU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ALLERGY; ANEMIA; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; BONE MARROW; BURST FORMING UNIT E; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COLONY FORMING UNIT; DOPING; ERYTHROCYTE APLASIA; ERYTHROCYTOSIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEMANGIOBLASTOMA; HEMOGLOBINOPATHY; HEREDITARY HEMOLYTIC ANEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOXIA; IRON DEFICIENCY ANEMIA; MEASUREMENT; MYELOPROLIFERATIVE DISORDER; PATHOPHYSIOLOGY; PLASMA HALF LIFE; POLYCYTHEMIA; POLYCYTHEMIA VERA; PREMATURITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; THROMBOSIS; UREMIA; VON HIPPEL LINDAU DISEASE;

ANEMIA; ERYTHROPOIETIN; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOASSAY; KIDNEY FAILURE, CHRONIC; SPORTS MEDICINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33644687429     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456306776021553     Document Type: Review

References (71)

1. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324: 1339-44
2. Chikuma M, Masuda S, Kobayashi T, Nagao M, Sasaki R. Tissue regulation of erythropoietin in the murine kidney, brain and uterus. Am J Physiol Endocrinol Metab 2000; 279: 1242-8
3. Nielson OJ, Thayson JH. Erythropoietin deficiency in acute renal failure. Lancet 1989; 1: 624-5
4. Winnearl C, Oliver D, Pippard M, Reid C, Downing MR, Cotes PM. Effects of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic dialysis. Lancet 1986; 2: 1175-80
5. Fischl M, Galpin JE, Levine JG, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322: 1488-93
6. Miller CB. The use of erythropoietin in cancer patients. Hematol Oncol Ann 1994; 2: 288-96
7. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anaemia in inflammatory bowel disease. N Engl J Med 1996; 334: 619-23
8. Shannon KM, Mentzer WC, Abels RI, et al. Recombinant human erythropoietin in the anaemia of prematurity: results from a placebo controlled pilot study. J Paediatr 1991; 118: 949-55
9. Pearson TC, Messinezy M. Investigation of patients with polycythemia. Postgrad Med J 1996; 72: 519-24
10. Winnearls CG. Erythropoietin. Proc R Coll Phys Edinburgh 1992; 22: 426-43
11. Lai P-H, Everett R, Wang FF, et al. Structural characterisation of human erythropoietin. J Biol Chem 1986; 261: 3116-21
12. Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guys Hosp Rep 1836; 1: 338-79
13. Carnot P, Deflandre C. Sur l'activite hemopoietique du serum au cours de la regeneration du sang. C R Acad Sci (Paris) 1906; 143: 384-6
14. Bondsdorff E, Jalavisto E. A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand 1948; 16: 150-70
15. Jacobson LO, Goldwasser E, Fried W, Ptzak L. Role of the kidney in erythropoiesis. Nature 1957; 179: 633-4
16. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-64
17. Lin F-K, Suggs S, Lin C-H, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580-4
18. Jacobs K, Shoemaker C, Rundersforf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-10
19. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-8
20. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-8
21. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 2005; 365: 1054-61
22. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8
23. Fried W, Plzak LF, Jacobson LO, Goldwasser E. Studies on erythropoiesis iii. Factors controlling erythropoietin production. Proc Soc Exp Biol Med 1957; 94: 84-9
24. Cotes PM, Bangham DR. Bioassay of erythropoietin in mice made polycythaemic by exposure to air at a reduced pressure. Nature 1961; 191: 1065-7
25. Krantz SB, Gallien-Lartigue O, Goldwasser E. The effect of erythropoietin in heme synthesis by marrow cells in vitro. J Biol Chem 1993; 238: 4085-90
26. Sherwood JB, Goldwasser E. A radioimmunoassay for erythropoietin. Blood 1; 54: 885-93
27. Cotes PM. Immunoreactive erythropoietin in serum. Br J Haematol 1982; 50: 427-38
28. Document for special controls for erythropoietin assay premarket notifications (510(k)s): guidance for industry. 1999. www.fda.gov/cdrh/ode/2241. pdf
29. Bechensteen AG, Lappin TR, Marsden J, Muggleston D, Cotes PM. Unreliability in immunoassays of erythropoietin: anomalous estimates with an assay kit. Br J Haematol 1993; 83: 663-4
30. Marsden JT, Sherwood RA, Peters TJ. Evaluation of six erythropoietin kits. Ann Clin Biochem 1999; 36: 380-7
31. NCCLCS. How to define, determine and utilize reference intervals in the clinical laboratory NCCLS Document C28-A 1995, volume 5
32. Chiesa ME, Fink NE. Reference intervals for erythropoietin measurement by the JCL EIA assay need to be determined locally. Clin Chem Lab Med 2000; 38: 65-6
33. Wide L, Bengtsson C, Birgegard G. Circadium rhythm of erythropoietin in human serum. Br J Haematol 1989; 72: 85-90
34. Pressac M, Morgant G, Farnier MA, Aymard P. Enzyme immunoassay of serum erythropoietin in healthy children: reference values. Ann Clin Biochem 1991; 28: 345-50
35. Marsden JT, Sherwood RA. Audit of requests received by the supraregional assay service for erythropoietin. Clin Chim Acta 2005; 355: 216
36. Mossuz P, Girodon F, Hermouet S, et al. Serum erythropoietin measured by chemiluminescent immunometric assay: an accurate diagnostic test for absolute erythrocytosis. Clin Chem 2005; 51: 1018-21
37. Marsden JT, Day P, Ellis R, Marwah S, Savage G, Sinclair C. A sample distribution programme for erythropoietin (in press)
38. Jelkmann W. Erythropoietin. J Endocrinol Invest 2003; 26: 832-7
39. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic performance. Adv Intern Med 1991; 36: 399-424
40. Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 2002; 85: 561-3
41. Lasne F, de Ceaurri J. Recombinant erythropoietin in urine. Nature 2000; 405: 635
42. De Almeida Bento RM, Pinto Damasceno LM, De Aquino Neto FR. Recombinant human erythropoietin in sports: a review. Rev Bras Med Esporte 2003; 9: 181-90
43. Erslev AJ, Caro J, Miller O, Silver R. Plasma erythropoietin in health and disease. Ann Clin Lab Sci 1980; 10: 250-7
44. Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979; 93: 449-58
45. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-94
46. Pearson TC, Guthrie DL, Simpson J, et al. Red cell mass and plasma volume interpretation in normal adults. Br J Haematol 1995; 89: 748-56
47. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations on polycythaemia vera based on Polycythaemia Vera Study Group protocols. Semin Haematol 1986; 23: 132-43
48. Messinezy M, Pearson TC. Diagnosis of polycythemia. J Clin Pathol 1998; 51: 1-4
49. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004; 10: 1194-8
50. Messinezy M, Westwood NB, El-Hemaidi I, Marsden JT, Sherwood RS, Pearson TC. Erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol 2002; 117: 47-53
51. Pavlisa G, Vrbanic V, Kusec V, Jaksic B. Erythropoietin response after correction of severe hypoxaemia due to acute respiratory failure in chronic pulmonary disease patients. Clin Sci 2004; 106: 43-51
52. Monge CC, Arregui A, Leon-Velarde F. Pathophysiology and epidemiology of chronic mountain sickness. Int J Sports Med 1992; 13: 79-81
53. Wajcman H, Galacteros F. Abnormal haemoglobins with high oxygen affinity and erythrocytosis. Hematol Cell Ther 1996; 38: 305-12
54. Rosove MH, Hocking WG, Canobbio MM, et al. Chronic hypoxaemia and decompensated erythrocytosis in cyanotic congenital heart disease. Lancet 1986; 2: 313-5
55. Franek E, Kokot F, Wiecek A, et al. Erythropoietin concentration in cyst fluid in patients with simple renal cysts. Nephron 1994; 67: 431-5
56. Trimble M, Caro J, Talalla A, Brain M. Secondary erythrocytosis due to a cerebellar hemangioblastoma: demonstration of erythropoietin mRNA in the tumour. Blood 1991; 78: 599-601
57. Clifford SC, Maher ER. Von Hippel-Lindau disease: clinical and molecular perspectives. Adv Cancer Res 2001; 82: 85-105
58. Pearson TC, Messinezy M. Idiopathic erythrocytosis, diagnosis and clinical management. Pathol Biol 2001; 49: 170-7
59. Winneals CG, Oliver DO, Pippard MJ. Effects of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-8
60. Esbach JW, Egrie JC, Downing MR. Correction of the anaemia of end stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8
61. Macdougall IC, Matcham J, Gray SJ. Correction of anaemia with darbopoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003; 18: 576-81
62. Osterborg A. New erythropoietic proteins: rationale and clinical data. Semin Oncol 2004; 31: 12
63. Kochendoerfer GG, Shiah-Yun C, Feng M, et al. Design and chemical synthesis of a homogenous polymer-modified erythropoiesis protein. Science 2003; 229: 884-7
64. Wrighton NC, Farrell FX, Chnag R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273: 458
65. Ng T, Marx G, Littlewood T, Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J 2003; 79: 367-76
66. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anaemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-7
67. Casadevall N, Nataf J, Viron B. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-75
68. Buemi M, Grasso G, Corico F, et al. In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid haemorrhage. Eur J Pharmacol 2000; 392: 31-4
69. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505
70. Lipton S. Erythropoietin for neurological protection and diabetic neuropathy. N Engl J Med 2004; 350: 2516-7
71. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100: 6741-6